(P143) Advanced Glycation Endproducts: The Sweet Tooth of Radiation Toxicity

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

The therapeutic index of treating cancer with ionizing radiation (IR) can be increased by minimizing normal tissue toxicity. Unfortunately, the therapies that have been developed to date have had limited efficacy. Therefore, identifying novel targets to protect normal tissue is essential during treatment.

Colin E. Champ, MD, Lianjin Jin, MD, PhD, Nicole L. Simone, MD; Department of Radiation Oncology, University of Pittsburgh Cancer Institute; UPMC CancerCenter, UPMC St. Margaret; Kimmel Cancer Center and Jefferson Medical College of Thomas Jefferson University

Purpose and Objectives: The therapeutic index of treating cancer with ionizing radiation (IR) can be increased by minimizing normal tissue toxicity. Unfortunately, the therapies that have been developed to date have had limited efficacy. Therefore, identifying novel targets to protect normal tissue is essential during treatment. Advanced glycation end products (AGEs), such as Nε-(carboxymethyl)-lysine (CML) and pentoside, may be one such class of molecules. AGEs occur when glucose is oxidized and forms irreversible crosslinks with collagen. This allows for sustained/chronic damage. AGEs are thought to be responsible for the end-organ damage noted in diabetics with chronic hyperglycemia, such as nephropathy, cataracts, and retinopathy, when ultraviolet irradiation (UVIR) interacts with the optical structures, inducing collagen crosslinks. Since UVIR induces most of its damage by free radicals, AGEs may be responsible in part for IR treatment–associated normal tissue toxicity. Therefore, we sought to determine if AGEs are induced by IR and if they are sustained over an extended period of time.

Materials and Methods: HEK293 cells were exposed to sham irradiation or 6 Gy of ionizing radiation (PanTek X-RAD 320 irradiator) and collected at 0.5, 3, and 24 hours after radiation exposure. Cells were collected, lysed with RIPA buffer (50 mM Tris-Cl, 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 × Mini protease inhibitor cocktail and phosphatase inhibitor cocktail), and quantified with BCA protein assay kit (Thermo Scientific, IL). AGE levels were then measured using a CML enzyme-linked immunosorbent assay (ELISA test) in our samples and compared with the four-parameter standard curve for the CML standards (Echelon Bioscience, UT).

Results: Twenty-four hours after irradiation, AGE production was elevated to 101.8 ng/dL vs 74.5 ng/dL in the control arm. The time course revealed that AGEs were induced and maintained at a level above 100 ng/dL at all time points, including 0.5, 3, and 24 hours. At the 0.5- and 24-hour time points, AGE levels were elevated to 103.9 vs 65.6 ng/dL in the control and 109.4 vs 86.1 ng/dL in the control arm, respectively. This increase was significant at all time points, with a P value < .001.

Conclusions: AGE formation may be a potential cause of acute and chronic toxicity from radiation. We have demonstrated for the first time that AGEs are induced by IR and may be a potential target to reduce toxicity. AGE inhibitors, such as carnosine, have already been developed and may potentially be used therapeutically to inhibit AGE formation and reduce radiation toxicity.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content